Published in Proc Natl Acad Sci U S A on January 27, 2005
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene (2010) 1.63
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag (2008) 1.59
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood (2005) 1.23
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood (2007) 1.14
Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol (2011) 1.06
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem (2010) 0.96
Oncogenes come of age. Cold Spring Harb Symp Quant Biol (2005) 0.95
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer (2010) 0.95
Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol (2010) 0.94
Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel) (2010) 0.92
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med (2012) 0.88
Development of an effective therapy for chronic myelogenous leukemia. Cancer J (2011) 0.87
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. Leukemia (2010) 0.85
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer. BMC Cancer (2005) 0.83
Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges. ACS Chem Biol (2014) 0.82
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. Biologics (2007) 0.79
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics (2007) 0.79
A novel quantitative kinase assay using bacterial surface display and flow cytometry. PLoS One (2013) 0.78
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway. PLoS One (2013) 0.77
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia. Braz J Med Biol Res (2014) 0.76
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep (2015) 0.75
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter (2011) 0.75
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Curr Med Chem (2011) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med (2003) 6.68
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 5.95
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Structural organization of the bcr gene and its role in the Ph' translocation. Nature (1985) 4.08
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 3.86
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood (2000) 2.67
Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies. Adv Enzymol Relat Areas Mol Biol (1977) 2.62
Constitutive synthesis of interleukin-3 by leukaemia cell line WEHI-3B is due to retroviral insertion near the gene. Nature (1985) 2.41
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med (2004) 2.23
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene (2003) 1.96
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res (2004) 1.90
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 1.72
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 1.51
Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev (2003) 1.47
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem (2002) 1.40
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res (2002) 1.29
Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. Oncogene (1987) 1.26
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood (2002) 1.10
Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol (2003) 1.03
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets (2001) 0.89
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell (2005) 3.56
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol (2002) 1.58
JAKs, STATs and Src kinases in hematopoiesis. Oncogene (2002) 1.56
Activation of p38alpha/beta MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo. J Cell Biol (2006) 1.52
Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci U S A (2009) 1.48
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res (2005) 1.46
Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle (2010) 1.40
Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res (2005) 1.37
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer (2010) 1.34
Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci U S A (2004) 1.32
JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors. Proc Natl Acad Sci U S A (2002) 1.22
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res (2011) 1.08
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer (2010) 1.05
JLP associates with kinesin light chain 1 through a novel leucine zipper-like domain. J Biol Chem (2005) 1.03
Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol (2003) 1.03
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol (2009) 1.00
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem (2007) 0.98
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorg Med Chem (2010) 0.97
An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. Cell Rep (2012) 0.97
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology (2011) 0.95
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome. J Biol Chem (2010) 0.95
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. Gastroenterology (2012) 0.92
Myb permits multilineage airway epithelial cell differentiation. Stem Cells (2014) 0.90
JNK-interacting leucine zipper protein is a novel scaffolding protein in the Galpha13 signaling pathway. Biochemistry (2005) 0.88
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem (2008) 0.87
Regulation of neurite outgrowth by interactions between the scaffolding protein, JNK-associated leucine zipper protein, and neuronal growth-associated protein superior cervical ganglia clone 10. J Biol Chem (2009) 0.87
Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene (2002) 0.86
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood (2004) 0.85
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. Bioorg Med Chem (2005) 0.85
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
Endodermal differentiation of murine embryonic carcinoma cells by retinoic acid requires JLP, a JNK-scaffolding protein. J Cell Biochem (2006) 0.84
Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper protein. Neoplasia (2011) 0.84
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development. Proc Natl Acad Sci U S A (2014) 0.83
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg Med Chem Lett (2004) 0.83
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J (2012) 0.82
Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood (2004) 0.81
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation. Genes Cancer (2010) 0.81
Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice. Cell Cycle (2012) 0.81
Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther (2014) 0.80
c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. J Biol Chem (2003) 0.80
Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells. Blood (2002) 0.79
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharm Res (2012) 0.79
Cooperativity of Cdk4R24C and Ras in melanoma development. Cell Cycle (2010) 0.79
p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts. Cancer Res (2007) 0.79
Activation of the Jak3 pathway and myeloid differentiation. Leuk Lymphoma (2005) 0.78
Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines. Bioorg Med Chem Lett (2009) 0.78
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway. PLoS One (2013) 0.77
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies. J Med Chem (2012) 0.77
Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma. Clin Cancer Res (2012) 0.77
p89c-Myb is not required for fetal or adult hematopoiesis. Genesis (2010) 0.77
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J Med Chem (2013) 0.77
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent. Org Biomol Chem (2013) 0.77
A novel role of the scaffolding protein JLP in tuning CD40-induced activation of dendritic cells. Immunobiology (2012) 0.76
Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors. Bioorg Med Chem (2005) 0.76
Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs (2012) 0.76
A role for Cdk4 in angiogenesis. Cell Cycle (2010) 0.75
Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cells. Nucl Med Biol (2007) 0.75
Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis. Proc Natl Acad Sci U S A (2013) 0.75